No Data
No Data
Guggenheim Downgrades Neumora Therapeutics to Neutral
William Blair Downgrades Neumora Therapeutics(NMRA.US) to Hold Rating
Neumora Therapeutics Cut to Hold From Buy by Stifel
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'
Express News | Neumora Therapeutics Shares Down 11.2% Premarket After Johnson & Johnson Stops Studies of Rival Depression Drug
Douglas Tsao Recommends 'Buy' for Neumora Therapeutics Due to Navacaprant's Market Potential and Differentiated Pharmacology